STOCK TITAN

Zura Bio (NASDAQ: ZURA) investors approve board slate, auditor and 2023 equity plan changes

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Zura Bio Limited held its Annual General Meeting of Shareholders on June 17, 2026, where a quorum was present. Shareholders approved an amendment and restatement of the company’s 2023 Equity Incentive Plan, which became effective immediately upon approval.

All eight director nominees were elected to serve until the next annual general meeting or earlier departure. Shareholders also ratified the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026. Because the director slate, auditor ratification and equity plan proposals all received sufficient support, the contingency proposal to adjourn the meeting was not submitted for a vote.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Equity plan approval votes for 38,850,373 votes For amended and restated 2023 Equity Incentive Plan
Equity plan votes against 17,403,607 votes Against amended and restated 2023 Equity Incentive Plan
Equity plan broker non-votes 18,267,509 votes Broker non-votes on equity plan proposal
Auditor ratification votes for 74,323,697 votes For ratification of WithumSmith+Brown, PC
Auditor ratification votes against 30,527 votes Against ratification of WithumSmith+Brown, PC
Director example votes for 56,209,068 votes For election of director nominee Mark Eisner
Director example votes against 291,173 votes Against election of director nominee Daniel Becker
Equity Incentive Plan financial
"approved an amendment and restatement of the Company’s 2023 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
ordinary resolution regulatory
"the election, by ordinary resolution, of the eight (8) directors listed below"
An ordinary resolution is a decision made by shareholders at a company meeting that is approved when more than half of the votes cast are in favor. Think of it like a household vote where a majority decides routine matters — it covers everyday corporate actions such as approving directors, routine policy changes, or distributions, and matters to investors because these majority-approved choices shape governance, management authority, and the company’s near-term direction.
independent registered public accounting firm regulatory
"the appointment by the Audit Committee of the Board of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Broker Non-Votes financial
"For | | Against | | Abstain | | Broker Non-Votes 38,850,373"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Emerging growth company regulatory
"Emerging growth company x"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001855644 0001855644 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 8-K

 

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 17, 2026

 

Zura Bio Limited

(Exact name of registrant as specified in its charter)

 

 

  

Cayman Islands   001-40598   98-1725736
(State or other jurisdiction of
incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

1489 W. Warm Springs Rd. #110

Henderson, NV 89014

 (Address of principal executive offices, including zip code)

 

(702) 825-9872

 (Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Class A Ordinary Shares, par value $0.0001 per share   ZURA   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers

 

On June 17, 2026, Zura Bio Limited (the “Company”) held its Annual General Meeting of Shareholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the shareholders of the Company approved an amendment and restatement of the Company’s 2023 Equity Incentive Plan (the “Amended 2023 Plan”). The Company’s board of directors previously approved the Amended 2023 Plan on April 23, 2026, subject to approval of the shareholders at the Annual Meeting. The Amended 2023 Plan became effective immediately upon shareholder approval at the Annual Meeting.

 

The material terms of the Amended 2023 Plan are described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2026 (the “Proxy Statement”) in the section entitled “Proposal 3: Approve the Amended and Restated 2023 Zura Bio Limited Equity Incentive Plan”. The description and terms of the Amended 2023 Plan contained herein and in the Proxy Statement are qualified in their entirety by the text of the Amended 2023 Plan, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

As referenced above, on June 17, 2026, the Company held its Annual Meeting, at which a quorum was present. At the Annual Meeting, the shareholders of the Company voted on the following four proposals: (1) the election, by ordinary resolution, of the eight (8) directors listed below (the “Director Nominees”) to the Company’s Board of Directors (the “Board”) to hold office until the next annual general meeting of shareholders or until their respective successors have been elected and qualified, or until their earlier death, resignation or removal (“Proposal 1”); (2) the ratification, by ordinary resolution, of the appointment by the Audit Committee of the Board of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 2”); (3) the approval, by ordinary resolution, of the Amended 2023 Plan (“Proposal 3”); and (4) the approval, by ordinary resolution, of the adjournment of the Annual Meeting by the chairman thereof to a later date, if necessary, for the purpose of soliciting additional proxies in favor of Proposals 1, 2 and 3, in the event the Company does not receive the requisite shareholder votes to approve Proposals 1, 2 and 3 (“Proposal 4”). Each of these proposals is described in greater detail in the Proxy Statement. The final results of the voting on each proposal are set forth below.

 

Proposal 1 - Election of Directors.

 

The Company’s shareholders elected the Director Nominees as directors of the Company, each to hold office until the next annual general meeting of shareholders or until their respective successors have been elected and qualified, or until their earlier death, resignation or removal. The votes cast were as follows:

 

Nominee  For  Against  Abstain  Broker Non-Votes
Daniel Becker  55,968,512  291,173  20,958  18,267,509
Mark Eisner  56,209,068  49,466  22,109  18,267,509
Jennifer Jarrett  39,788,639  16,471,044  20,958  18,267,511
Sandeep Kulkarni  56,250,391  8,292  21,960  18,267,509
Amit Munshi  40,229,829  16,027,697  23,115  18,267,511
Ajay Nirula  56,249,212  8,319  23,113  18,267,508
Steven Schoch  56,197,526  61,025  22,093  18,267,508
Parvinder Thiara  55,766,669  490,857  23,115  18,267,511

 

 

 

 

Proposal 2 - Ratification of the Appointment of Independent Registered Public Accounting Firm.

 

The Company’s shareholders ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes cast were as follows:

 

For  Against  Abstain
74,323,697  30,527  193,928

 

Proposal 3 - Approval of the Amended and Restated 2023 Zura Bio Limited Equity Incentive Plan

 

The Company’s shareholders approved the amendment and restatement of the Company’s 2023 Equity Incentive Plan. The votes cast were as follows:

 

For  Against  Abstain  Broker Non-Votes
38,850,373  17,403,607  26,663  18,267,509

 

Proposal 4 - Adjournment Proposal.

 

Proposal 4 was to approve an adjournment of the Annual Meeting by the chairman thereof to a later date, if necessary, for the purpose of soliciting additional proxies in favor of Proposals 1, 2 and 3, in the event the Company did not receive the requisite shareholder votes to approve Proposals 1, 2 and 3. As Proposals 1, 2 and 3 were approved by the requisite number of votes, Proposal 4 was not put to a vote of the shareholders at the Annual Meeting.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
10.1   Amended and Restated 2023 Equity Incentive Plan
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 18, 2026

 

  ZURA BIO LIMITED
   
  By: /s/ Kim Davis
    Kim Davis
    Chief Operating Officer, Chief Legal Officer and Corporate Secretary

 

 

 

FAQ

What did ZURA shareholders approve at the June 17, 2026 annual meeting?

Shareholders approved all main items: eight directors, the amended and restated 2023 Equity Incentive Plan, and ratified WithumSmith+Brown, PC as auditor for the year ending December 31, 2026.

Was ZURA’s amended 2023 Equity Incentive Plan approved by shareholders?

Yes. The amended and restated 2023 Equity Incentive Plan was approved with 38,850,373 votes for, 17,403,607 against, 26,663 abstentions and 18,267,509 broker non-votes at the June 17, 2026 meeting.

Which directors were elected to ZURA’s board at the 2026 annual meeting?

Shareholders elected Daniel Becker, Mark Eisner, Jennifer Jarrett, Sandeep Kulkarni, Amit Munshi, Ajay Nirula, Steven Schoch and Parvinder Thiara as directors, each to serve until the next annual general meeting or earlier departure.

Did ZURA shareholders ratify the 2026 independent auditor?

Yes. Shareholders ratified WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 74,323,697 votes for, 30,527 against and 193,928 abstentions.

Was the proposal to adjourn ZURA’s 2026 annual meeting used?

No. The adjournment proposal was not put to a vote because the director elections, auditor ratification and the amended 2023 Equity Incentive Plan were all approved by the requisite number of shareholder votes.

Filing Exhibits & Attachments

4 documents